Financhill
Sell
45

BPMC Quote, Financials, Valuation and Earnings

Last price:
$110.07
Seasonality move :
4.12%
Day range:
$104.73 - $110.28
52-week range:
$72.24 - $121.90
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
15.89x
P/B ratio:
22.33x
Volume:
970.1K
Avg. volume:
755.8K
1-year change:
38.64%
Market cap:
$7B
Revenue:
$249.4M
EPS (TTM):
-$2.11

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
BPMC
Blueprint Medicines
$145.5M -$0.69 101.97% -63.42% $125.47
BMRN
Biomarin Pharmaceutical
$711.3M $0.71 10.19% 566.24% $97.16
LLY
Eli Lilly and
$13.7B $5.28 49.68% 124.93% $977.47
PTCT
PTC Therapeutics
$272.3M -$0.97 -37.97% -75.73% $58.07
REGN
Regeneron Pharmaceuticals
$3.8B $11.25 9.55% 7.9% $1,005.65
VRTX
Vertex Pharmaceuticals
$2.8B $4.03 10.63% 10.37% $489.81
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
BPMC
Blueprint Medicines
$110.05 $125.47 $7B -- $0.00 0% 15.89x
BMRN
Biomarin Pharmaceutical
$61.53 $97.16 $11.7B 36.84x $0.00 0% 4.39x
LLY
Eli Lilly and
$725.72 $977.47 $688.9B 78.46x $1.30 0.72% 16.06x
PTCT
PTC Therapeutics
$43.08 $58.07 $3.3B -- $0.00 0% 3.65x
REGN
Regeneron Pharmaceuticals
$693.23 $1,005.65 $76.2B 17.15x $0.00 0% 5.76x
VRTX
Vertex Pharmaceuticals
$416.96 $489.81 $107.4B 26.10x $0.00 0% 10.21x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
BPMC
Blueprint Medicines
55.25% 2.180 6.59% 3.10x
BMRN
Biomarin Pharmaceutical
9.9% 0.523 4.44% 2.39x
LLY
Eli Lilly and
68.61% 1.159 3.9% 0.63x
PTCT
PTC Therapeutics
-37.06% -0.152 9.99% 1.99x
REGN
Regeneron Pharmaceuticals
6.34% 1.263 1.71% 4.34x
VRTX
Vertex Pharmaceuticals
-- 1.137 -- 2.08x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
BPMC
Blueprint Medicines
$126.3M -$49M -23.14% -50.13% -29.05% -$13.7M
BMRN
Biomarin Pharmaceutical
$557.3M $113.9M 5.27% 6.29% 18.43% $200.3M
LLY
Eli Lilly and
$9.3B $4.4B 21.5% 66.4% 15.57% -$458.9M
PTCT
PTC Therapeutics
$185.9M -$52M -425.51% -- -28.65% -$87.8M
REGN
Regeneron Pharmaceuticals
$3.2B $1.2B 16.02% 17.19% 40.5% $1B
VRTX
Vertex Pharmaceuticals
$2.4B $1.1B -2.89% -2.89% 44.43% $1.3B

Blueprint Medicines vs. Competitors

  • Which has Higher Returns BPMC or BMRN?

    Biomarin Pharmaceutical has a net margin of -43.9% compared to Blueprint Medicines's net margin of 14.23%. Blueprint Medicines's return on equity of -50.13% beat Biomarin Pharmaceutical's return on equity of 6.29%.

    Company Gross Margin Earnings Per Share Invested Capital
    BPMC
    Blueprint Medicines
    98.49% -$0.89 $699.7M
    BMRN
    Biomarin Pharmaceutical
    74.73% $0.55 $6B
  • What do Analysts Say About BPMC or BMRN?

    Blueprint Medicines has a consensus price target of $125.47, signalling upside risk potential of 14.02%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $97.16 which suggests that it could grow by 57.91%. Given that Biomarin Pharmaceutical has higher upside potential than Blueprint Medicines, analysts believe Biomarin Pharmaceutical is more attractive than Blueprint Medicines.

    Company Buy Ratings Hold Ratings Sell Ratings
    BPMC
    Blueprint Medicines
    9 5 1
    BMRN
    Biomarin Pharmaceutical
    14 5 0
  • Is BPMC or BMRN More Risky?

    Blueprint Medicines has a beta of 0.610, which suggesting that the stock is 39.048% less volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.289, suggesting its less volatile than the S&P 500 by 71.112%.

  • Which is a Better Dividend Stock BPMC or BMRN?

    Blueprint Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Blueprint Medicines pays -- of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BPMC or BMRN?

    Blueprint Medicines quarterly revenues are $128.2M, which are smaller than Biomarin Pharmaceutical quarterly revenues of $745.7M. Blueprint Medicines's net income of -$56.3M is lower than Biomarin Pharmaceutical's net income of $106.1M. Notably, Blueprint Medicines's price-to-earnings ratio is -- while Biomarin Pharmaceutical's PE ratio is 36.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Blueprint Medicines is 15.89x versus 4.39x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BPMC
    Blueprint Medicines
    15.89x -- $128.2M -$56.3M
    BMRN
    Biomarin Pharmaceutical
    4.39x 36.84x $745.7M $106.1M
  • Which has Higher Returns BPMC or LLY?

    Eli Lilly and has a net margin of -43.9% compared to Blueprint Medicines's net margin of 8.48%. Blueprint Medicines's return on equity of -50.13% beat Eli Lilly and's return on equity of 66.4%.

    Company Gross Margin Earnings Per Share Invested Capital
    BPMC
    Blueprint Medicines
    98.49% -$0.89 $699.7M
    LLY
    Eli Lilly and
    81.02% $1.07 $45.4B
  • What do Analysts Say About BPMC or LLY?

    Blueprint Medicines has a consensus price target of $125.47, signalling upside risk potential of 14.02%. On the other hand Eli Lilly and has an analysts' consensus of $977.47 which suggests that it could grow by 34.69%. Given that Eli Lilly and has higher upside potential than Blueprint Medicines, analysts believe Eli Lilly and is more attractive than Blueprint Medicines.

    Company Buy Ratings Hold Ratings Sell Ratings
    BPMC
    Blueprint Medicines
    9 5 1
    LLY
    Eli Lilly and
    15 6 0
  • Is BPMC or LLY More Risky?

    Blueprint Medicines has a beta of 0.610, which suggesting that the stock is 39.048% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.729%.

  • Which is a Better Dividend Stock BPMC or LLY?

    Blueprint Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.72% to investors and pays a quarterly dividend of $1.30 per share. Blueprint Medicines pays -- of its earnings as a dividend. Eli Lilly and pays out 77.65% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios BPMC or LLY?

    Blueprint Medicines quarterly revenues are $128.2M, which are smaller than Eli Lilly and quarterly revenues of $11.4B. Blueprint Medicines's net income of -$56.3M is lower than Eli Lilly and's net income of $970.3M. Notably, Blueprint Medicines's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 78.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Blueprint Medicines is 15.89x versus 16.06x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BPMC
    Blueprint Medicines
    15.89x -- $128.2M -$56.3M
    LLY
    Eli Lilly and
    16.06x 78.46x $11.4B $970.3M
  • Which has Higher Returns BPMC or PTCT?

    PTC Therapeutics has a net margin of -43.9% compared to Blueprint Medicines's net margin of -54.2%. Blueprint Medicines's return on equity of -50.13% beat PTC Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BPMC
    Blueprint Medicines
    98.49% -$0.89 $699.7M
    PTCT
    PTC Therapeutics
    94.49% -$1.39 -$769.2M
  • What do Analysts Say About BPMC or PTCT?

    Blueprint Medicines has a consensus price target of $125.47, signalling upside risk potential of 14.02%. On the other hand PTC Therapeutics has an analysts' consensus of $58.07 which suggests that it could grow by 34.8%. Given that PTC Therapeutics has higher upside potential than Blueprint Medicines, analysts believe PTC Therapeutics is more attractive than Blueprint Medicines.

    Company Buy Ratings Hold Ratings Sell Ratings
    BPMC
    Blueprint Medicines
    9 5 1
    PTCT
    PTC Therapeutics
    6 3 1
  • Is BPMC or PTCT More Risky?

    Blueprint Medicines has a beta of 0.610, which suggesting that the stock is 39.048% less volatile than S&P 500. In comparison PTC Therapeutics has a beta of 0.619, suggesting its less volatile than the S&P 500 by 38.129%.

  • Which is a Better Dividend Stock BPMC or PTCT?

    Blueprint Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PTC Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Blueprint Medicines pays -- of its earnings as a dividend. PTC Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BPMC or PTCT?

    Blueprint Medicines quarterly revenues are $128.2M, which are smaller than PTC Therapeutics quarterly revenues of $196.8M. Blueprint Medicines's net income of -$56.3M is higher than PTC Therapeutics's net income of -$106.7M. Notably, Blueprint Medicines's price-to-earnings ratio is -- while PTC Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Blueprint Medicines is 15.89x versus 3.65x for PTC Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BPMC
    Blueprint Medicines
    15.89x -- $128.2M -$56.3M
    PTCT
    PTC Therapeutics
    3.65x -- $196.8M -$106.7M
  • Which has Higher Returns BPMC or REGN?

    Regeneron Pharmaceuticals has a net margin of -43.9% compared to Blueprint Medicines's net margin of 36.03%. Blueprint Medicines's return on equity of -50.13% beat Regeneron Pharmaceuticals's return on equity of 17.19%.

    Company Gross Margin Earnings Per Share Invested Capital
    BPMC
    Blueprint Medicines
    98.49% -$0.89 $699.7M
    REGN
    Regeneron Pharmaceuticals
    86.8% $11.54 $31.3B
  • What do Analysts Say About BPMC or REGN?

    Blueprint Medicines has a consensus price target of $125.47, signalling upside risk potential of 14.02%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $1,005.65 which suggests that it could grow by 45.07%. Given that Regeneron Pharmaceuticals has higher upside potential than Blueprint Medicines, analysts believe Regeneron Pharmaceuticals is more attractive than Blueprint Medicines.

    Company Buy Ratings Hold Ratings Sell Ratings
    BPMC
    Blueprint Medicines
    9 5 1
    REGN
    Regeneron Pharmaceuticals
    11 7 0
  • Is BPMC or REGN More Risky?

    Blueprint Medicines has a beta of 0.610, which suggesting that the stock is 39.048% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.098, suggesting its less volatile than the S&P 500 by 90.217%.

  • Which is a Better Dividend Stock BPMC or REGN?

    Blueprint Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Blueprint Medicines pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BPMC or REGN?

    Blueprint Medicines quarterly revenues are $128.2M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.7B. Blueprint Medicines's net income of -$56.3M is lower than Regeneron Pharmaceuticals's net income of $1.3B. Notably, Blueprint Medicines's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 17.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Blueprint Medicines is 15.89x versus 5.76x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BPMC
    Blueprint Medicines
    15.89x -- $128.2M -$56.3M
    REGN
    Regeneron Pharmaceuticals
    5.76x 17.15x $3.7B $1.3B
  • Which has Higher Returns BPMC or VRTX?

    Vertex Pharmaceuticals has a net margin of -43.9% compared to Blueprint Medicines's net margin of 37.71%. Blueprint Medicines's return on equity of -50.13% beat Vertex Pharmaceuticals's return on equity of -2.89%.

    Company Gross Margin Earnings Per Share Invested Capital
    BPMC
    Blueprint Medicines
    98.49% -$0.89 $699.7M
    VRTX
    Vertex Pharmaceuticals
    85.84% $4.01 $15.6B
  • What do Analysts Say About BPMC or VRTX?

    Blueprint Medicines has a consensus price target of $125.47, signalling upside risk potential of 14.02%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $489.81 which suggests that it could grow by 17.47%. Given that Vertex Pharmaceuticals has higher upside potential than Blueprint Medicines, analysts believe Vertex Pharmaceuticals is more attractive than Blueprint Medicines.

    Company Buy Ratings Hold Ratings Sell Ratings
    BPMC
    Blueprint Medicines
    9 5 1
    VRTX
    Vertex Pharmaceuticals
    17 11 2
  • Is BPMC or VRTX More Risky?

    Blueprint Medicines has a beta of 0.610, which suggesting that the stock is 39.048% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.399, suggesting its less volatile than the S&P 500 by 60.102%.

  • Which is a Better Dividend Stock BPMC or VRTX?

    Blueprint Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Blueprint Medicines pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BPMC or VRTX?

    Blueprint Medicines quarterly revenues are $128.2M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. Blueprint Medicines's net income of -$56.3M is lower than Vertex Pharmaceuticals's net income of $1B. Notably, Blueprint Medicines's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Blueprint Medicines is 15.89x versus 10.21x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BPMC
    Blueprint Medicines
    15.89x -- $128.2M -$56.3M
    VRTX
    Vertex Pharmaceuticals
    10.21x 26.10x $2.8B $1B

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is American Express Stock Going Lower?
Is American Express Stock Going Lower?

American Express Company (NYSE:AXP) has long been a Buffett favorite…

Cigna vs Costco Stock: Which Is Best?
Cigna vs Costco Stock: Which Is Best?

Cigna and Costco don’t usually go hand in hand but…

Will T-Mobile Stock Recover?
Will T-Mobile Stock Recover?

Last year was a stellar year for telecom giant T-Mobile…

Stock Ideas

Sell
46
Is AAPL Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 38x

Buy
51
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 115x

Buy
53
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 36x

Alerts

Buy
53
QMCO alert for Jan 18

Quantum [QMCO] is down 15.61% over the past day.

Sell
36
QRVO alert for Jan 18

Qorvo [QRVO] is up 14.47% over the past day.

Sell
31
ATEX alert for Jan 18

Anterix [ATEX] is up 11.14% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock